Ceftriaxone: Difference between revisions
No edit summary |
No edit summary |
||
| Line 25: | Line 25: | ||
'''| [[Ceftriaxone dosage and administration|Dosage and Administration]]''' | '''| [[Ceftriaxone dosage and administration|Dosage and Administration]]''' | ||
'''| [[Ceftriaxone Compatibility and Stability|Compatibility and Stability]]''' | '''| [[Ceftriaxone Compatibility and Stability|Compatibility and Stability]]''' | ||
'''| [[Ceftriaxone how supplied|How Supplied]]''' | '''| [[Ceftriaxone how supplied|How Supplied]]''' | ||
'''| [[Ceftriaxone labels and packages|Labels and Packages]]''' | '''| [[Ceftriaxone labels and packages|Labels and Packages]]''' | ||
Revision as of 18:43, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Overview
Ceftriaxone (INN) (IPA: Template:IPA) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to cefotaxime in terms of safety and efficacy. Ceftriaxone sodium is marketed by Hoffman-La Roche under the trade name Rocephin.
Category
Cephalosporins,third generation.
US Brand Names
CEFTRIAXONE® ,ROCEPHIN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility and Stability | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/050796lbl.pdf